Is there a role for allogeneic transplantation in chronic myeloid leukemia?

Expert Review of Hematology

Volumn 6, Issue 6, 2013, Pages 759-765

  Benyamini, Noam ^a   Rowe, Jacob M ^a,b,c  

^a Rambam Health Care Campus ^*  (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Allogeneic transplantation; Chronic myeloid leukemia; Stem cell transplantation; TKIs; Treatment

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLAST CELL CRISIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; FOLLOW UP; GENE MUTATION; GROWTH DISORDER; HELP SEEKING BEHAVIOR; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84887984432     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.849571     Document Type: Review

References (57)

1. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J. Natl Cancer Inst. 25, 85-109 (1960
2. Kantarjian HM, Giles FJ, Bhalla KN et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117(4), 1141-1145 (2011
3. Kantarjian HM, Shah NP, Cortes JE et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119(5), 1123-1129 (2012
4. Cortes JE, Kim DW, Kantarjian HM et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. J. Clin. Oncol. 30(28), 3486-3492 (2012
5. Cortes JE, Kantarjian H, Shah NP et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 367(22), 2075-2088 (2012
6. Cortes J, Lipton JH, Rea D et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 120(13), 2573-2580 (2012
7. Mahon FX, Delbrel X, Cony-Makhoul P et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J. Clin. Oncol. 20(1), 214-220 (2002
8. Bonifazi F, de Vivo A, Rosti G et al. Chronic myeloid leukemia and interferonalpha: A study of complete cytogenetic responders. Blood 98(10), 3074-3081 (2001
9. Mahon FX, Rea D, Guilhot J et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11(11), 1029-1035 (2010
10. Ross DM, Branford S, Seymour JF et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24(10), 1719-1724 (2010
11. Ross DM, Branford S, Seymour JF et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 122(4), 515-522 (2013
12. Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci. 101(7), 1577-1581 (2010
13. Drummond MW, Heaney N, Kaeda J et al. A pilot study of continuous imatinib versus pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia 23(6), 1199-1201 (2009
14. Burchert A, Wolfl S, Schmidt M et al. Interferon-Alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101(1), 259-264 (2003
15. Dierks C, Beigi R, Guo GR et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14(3), 238-249 (2008
16. Tauchi T, Katagiri S, Okabe S, Minami Y, Naoe T, Ohyashiki K. Targeting the Hedgehog signaling pathway limits the self-renewal of BCR-ABL1 positive leukemia cells: Molecular mechanisms. Blood 120, 531a (2012
17. Buckner CD, Stewart P, Clift RA et al. Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp. Hematol. 6(1), 96-109 (1978
18. McGlave PB, De Fabritiis P, Deisseroth A et al. Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 343(8911), 1486-1488 (1994
19. Speck B, Bortin MM, Champlin R et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1(8378), 665-668 (1984
20. Thomas ED and Clift RA. Indications for marrow transplantation in chronic myelogenous leukemia. Blood 73(4), 861-864 (1989
21. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA. Validation and extension of the EBMT risk score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br. J. Haematol. 125(5), 613-620 (2004
22. Khoury HJ, Kukreja M, Goldman JM et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: A CIBMTR analysis. Bone Marrow Transplant. 47(6), 810-816 (2012
23. Goldman JM, Szydlo R, Horowitz MM et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82(7), 2235-2238 (1993
24. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N. Engl. J. Med. 338(14), 962-968 (1998
25. Laporte JP, Gorin NC, Rubinstein P et al. Cord-blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. N. Engl. J. Med. 335(3), 167-170 (1996
26. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84(6), 2036-2043 (1994
27. Radich JP, Gooley T, Bensinger W et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102(1), 31-35 (2003
28. Warlick E, Ahn KW, Pedersen TL et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 119(17), 4083-4090 (2012
29. Apperley JF, Mauro FR, Goldman JM et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Importance of a graft-versus-leukaemia effect. Br. J. Haematol. 69(2), 239-245 (1988
30. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann. Intern. Med. 108(6), 806-814 (1988
31. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83(11), 3377-3383 (1994
32. Arpinati M, Tolomelli G, Bochicchio MT et al. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. Biol. Blood Marrow Transplant. 19(5), 735-740 (2013
33. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348(11), 994-1004 (2003
34. Deininger M, O'Brien SG, Guilhot F et al. International randomized study of Interferon Vs STI 571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114, 1126 (2009
35. Hehlmann R, Berger U, Pfirrmann M et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109(11), 4686-4692 (2007
36. Lucas CM, Wang L, Austin GM et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 22(10), 1963-1966 (2008
37. Kantarjian HM, Talpaz M, O'Brien S et al. Survival benefit with imatinib mesylate versus interferon-Alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108(6), 1835-1840 (2006
38. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2260-2270 (2010
39. Kantarjian HM, Hochhaus A, Saglio G et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 12(9), 841-851 (2011
40. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6), 2303-2309 (2007
41. Hochhaus A, Baccarani M, Deininger M et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22(6), 1200-1206 (2008
42. Saussele S, Lauseker M, Gratwohl A et al Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115(10), 1880-1885 (2010
43. Jabbour E, Cortes J, Santos FP et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13), 3641-3647 (2011
44. Carpenter PA, Snyder DS, Flowers ME et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109(7), 2791-2793 (2007
45. Olavarria E, Siddique S, Griffiths MJ et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 110(13), 4614-4617 (2007
46. Passweg JR, Baldomero H, Gratwohl A et al The EBMT activity survey: 1990-2010. Bone Marrow Transplant. 47(7), 906-923 (2012
47. Hasford J, Baccarani M, Hoffmann V et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood 118(3), 686-692 (2011
48. Baccarani M, Deininger MW, Rosti G et al European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6), 872-884 (2013
49. Cortes JE, Kim DW, Pinilla-Ibarz L et al. A pivotal phase 2 trial of ponatinib in patients with Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-Month Follow-up of the PACE trial. Blood 120(21), 163 (2012
50. Rea D, Etienne G, Nicolini F et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia 26(10), 2254-2259 (2012
51. Ohanian M, Kantarjian HM, Quintas-Cardama A et al. The clinical impact of time to response in de novo accelerated phase Chronic Myeloid Leukemia (CML-AP). Blood 120(21), 72 (2012
52. Ross M, Branford S, Seymour J et al. Frequent and sustained drug-free remission in the Australasian CML 8 trial of imatinib withdrawal. Haematologica 97 (Suppl. 1), 74 (2012
53. Rea D, Rousselot P, Guilhot F et al. Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) patients with stable undetectable BCR-ABL transcripts. Blood 120(21), 916 (2012
54. Millot F, Baruchel A, Guilhot J et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J. Clin. Oncol. 29(20), 2827-2832 (2011
55. Zwaan CM, Rizzari C, Mechinaud F et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: Results of the CA180-018 phase I dose-escalation study of the innovative therapies for children with cancer consortium. J. Clin. Oncol. 31(19), 2460-2468 (2013
56. Narayanan KR, Bansal D, Walia R et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr. Blood Cancer 60(7), 1148-1153 (2013
57. Shima H, Tokuyama M, Tanizawa A et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J. Pediatr. 159(4), 676-681 (2011